Saudi Arabia, with its substantial economy, has seen a notable rise in the popularity of beauty and aesthetic treatments. The country's cultural liberalization has led to greater acceptance of cosmetic enhancements, creating a fertile market for products like Nabota. The Saudi Food and Drug Authority imposes stringent quality assessments for medical products, making market entry challenging. Nabota's approval underscores its compliance with these rigorous standards.
Nabota has previously secured approvals from major regulatory bodies, including the U.S. Food and Drug Administration , the European Medicines Agency , and Health Canada, attesting to its global recognition for quality and safety. The product is manufactured using Daewoong's proprietary HI-PURE™ Technology and vacuum drying processes, resulting in a high-purity botulinum toxin. This method ensures that over 98% of the 900 kDa complex is pure toxin, facilitating rapid and precise effects. Additionally, the production process minimizes the formation of inactive toxins, reducing the risk of resistance and enhancing safety.
The Saudi market is currently dominated by AbbVie's Botox, which shares the same molecular structure as Nabota. However, Nabota's demonstrated efficacy positions it as a strong competitor, with expectations of swift market penetration and increased share.
To commemorate the launch, Daewoong hosted a symposium on January 24 at the Fairmont Hotel in Riyadh, attended by approximately 300 local medical professionals. Dr. Hassan Galadari, a dermatologist from the United Arab Emirates, presented on "Changing the Game with Prabotulinum Toxin," sharing global clinical results and application insights related to Nabota. He highlighted that Nabota matches Botox in molecular size and has proven its efficacy and safety through international clinical trials and approvals. Dr. Galadari emphasized Nabota's superior performance in precision, durability, and patient satisfaction.
Dr. Amr Abduljabbar, a Saudi dermatologist who chaired the symposium, noted that the event showcased Nabota's manufacturing excellence and quality competitiveness, as well as global clinical outcomes and experiences from key opinion leaders. He expressed confidence that Nabota will become a game-changer in Saudi Arabia, a pivotal market in the Middle East and Africa.
Yoon Joon-soo, head of Daewoong's Nabota division, emphasized the product's global reach, stating that Nabota is the most exported high-purity, high-quality botulinum toxin from Korea, with approvals in 69 countries and export contracts with over 80 countries. He outlined the company's strategy to strengthen its presence in Saudi Arabia and expand throughout the Middle East and Africa.